Zikani Therapeutics, Inc

Call
Website
480 Arsenal St Ste 130
Watertown, MA 02472
+1 (617) 453-9091
http://zikani.com

Zikani Therapeutics, Inc., based in Watertown, MA, is at the forefront of precision oncology, developing targeted therapies aimed at improving patient outcomes for those suffering from cancer. Utilizing their proprietary AP3 platform, the company matches drug mechanisms to the biological drivers of cancer, enabling a more effective approach to treatment through their unique patient selection methods.

The company's pipeline focuses on DNA Damage Response and includes their lead program, ACR368, a selective kinase inhibitor currently in phase 2 clinical development. Zikani is committed to advancing impactful therapeutics through strategic partnerships and innovative technologies in the rapidly evolving field of oncology.

Generated from the website

Also at this address

Own this business?
See a problem?

You might also like

Drugs acting on the respiratory system

Exo Therapeutics, Inc

Exo Therapeutics, Inc., located in Cambridge, MA, is pioneering a new approach in medicine by unlocking challenging drug targets through its innovative Exosites platform. This comprehensive system is designed to modulate enzyme activity with precision and potency, primarily focusing on applications in oncology and inflammation. With a commitment to charting new territory in drug development, Exo Therapeutics is actively advancing its pipeline to create breakthrough medicines. Recent presentations at prominent conferences highlight the company's progress, including data on novel exosite inhibitors that disrupt pathological pathways in disease mechanisms. Generated from the website
Blood derivatives, Drugs acting on the respiratory system

C4T Securities Corporation

C4 Therapeutics, Inc. is a biotechnology company based in Watertown, MA, specializing in targeted protein degradation. Their innovative approach, known as Targeted Protein Degradation (TPD), aims to develop a new generation of medicines for treating various diseases. Through their TORPEDO platform and focus on target selection, C4 Therapeutics is dedicated to transforming lives by degrading disease-causing proteins. With a strong leadership team, board of directors, and scientific advisory board, C4 Therapeutics is committed to advancing their pipeline of therapies, including CFT7455, CFT1946, and CFT8919. They also collaborate with industry partners such as Roche, Biogen, Betta Merck, and others to further their research and development efforts. At C4 Therapeutics, their values, people, and dedication to scientific progress drive their mission to revolutionize the treatment of diseases through targeted protein degradation.Generated from the website
Industrial and labor consulting services, Drugs acting on the respiratory system

Seaside Therapeutics

Seaside Therapeutics, based in Cambridge, is a pioneering leader in rare disease medicine, exemplified by its commitment to advancing the rare disease community. Ultragenyx, a subsidiary of Seaside Therapeutics, is at the forefront of driving progress in the field of rare disease treatment, dedicated to propelling the rare disease community forward. Generated from their website's infomation
United States›Massachusetts›Watertown›Zikani Therapeutics, Inc

Partial Data by Infogroup (c) 2025. All rights reserved.